Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study

Heart Failure Clinical Trial

— ORACLE  

Official title:

Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05679713
• Other study ID #: PI21/00264
• Status: Recruiting
• Start date: September 5, 2022
• Est. completion date: December 1, 2024

Study information

• Verified date: January 2023
• Source: Hospital Universitari de Bellvitge
• Contact: Josep Comín Colet, MD, PhD
• Phone: +34 932607078
• Email: jcomin[@]bellvitgehospital.cat
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to develop and validate an improved, comprehensive risk assessment algorithm integrating blood RNA-based biomarkers, clinical, and patient-centered data and to assess the incremental predictive value (discrimination and reclassification) compared to a traditional risk model (change in the c-statistics for prediction of the primary endpoint).

Description:

The ORACLE study is a multicenter, observational, prospective, cross-sectional and longitudinal study integrated by 3 different cohorts for 1) RNA biomarker discovery (60 nested case-control sample), 2) model derivation (516 nested case-control sample) and 3) external validation (new prospective cohort of 558 consecutive patients recruited in 4 hospital centers) according to a TRIPOD Statement type 3 analysis. In total 1134 consecutive patients with a HF hospitalization or urgent HF visit < 30 days before inclusion and followed for 6 months will be studied.

This study include the discovery of novel RNA-based biomarkers using next-generation sequencing technology to define and validate a new biomarker set and clinical and patient-centered risk determinants definition. A new model will be constructed; training and internal validation in the derivation cohort using machine learning methods, and finally an external validation of the new next generation integrative risk assessment model will be performed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1134
• Est. completion date: December 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old.

• Patients with a recent (<30 days) acute decompensation of HF requiring intravenous diuretic therapy (either hospitalized or in ambulatory care) or intensification of oral diuretics (ambulatory care).

• HF diagnosis according to European Society of Cardiology (ESC) criteria.

• Written informed consent

• Patients receiving oral standard medication for chronic HF.

Exclusion Criteria:

• Age<18 years old.

• Death before hospital discharge.

• The patient is unable or unwilling to give the informed consent to participate.

• Unstable patients with signs of fluid overload or low cardiac output at the moment of enrollment.

Related Conditions & MeSH terms

• Heart Failure

Intervention

Diagnostic Test:
• Comprehensive risk assessment algorithm
Risk assessment algorithm including clinical and patient-centered information and a novel RNA-based biomarkers using next-generation sequencing technology.

Locations

Country	Name	City	State
Spain	University Hospital Bellvitge	L'Hospitalet de Llobregat	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Universitari de Bellvitge

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Explore the performance (sensibility and specificity) of the developed model according gender, LVEF (preserved or reduced left ventricle ejection fraction), comorbidity burden (Charlson Comorbidity Index) and frailty.		6 months
Primary	To compare the model performance of the comprehensive risk assessment algorithm with a traditional risk model to predict HF related hospitalizations or all-cause death	To compare in an external validation cohort of patients a recent acute HF event, the performance (discrimination, additive predictive value, and reclassification ability) of a comprehensive risk assessment algorithm with the performance of a traditional risk model to predict the occurrence of the primary composite clinical end-point of HF related hospitalizations (readmissions) or all-cause death at 180 days after hospital discharge or after an urgent HF visit (acute HF event requiring intravenous administration of diuretics without admission).	6 months
Secondary	To compare the model performance of the comprehensive risk assessment algorithm with a traditional risk model to predict the occurrence of HF-related hospitalizations (readmissions) or all-cause death at 30, and 90 days after hospital discharge.	The admission will be considered as HF-related if it suits with one of the following conditions: Cardiovascular cause hospitalization; Complication directly related with prior HF admission; Decompensation of prior disease or comorbidity	6 months
Secondary	To compare the model performance of the comprehensive risk assessment algorithm with a traditional risk model to predict the occurrence of HF-related hospitalizations (readmissions) at 30, 90, and 180 days after hospital discharge.		6 months
Secondary	To compare the model performance of the comprehensive risk assessment algorithm with a traditional risk model to predict the occurrence of all-cause death at 30, 90, and 180 days, after hospital discharge.		6 months